INDEX

Welcome Letter  3
Committee  4
Program Overview  5
Scientific Program  6
General Information  12
Sustainable Congress  18
List of Posters  19
Supporters  33
Exhibitors  35
Floorplan  37
Supported Symposia  39
Supporters Corporate Information  40
Exhibitors Corporate Information  44
Welcome Letter

Dear Friends and Colleagues,

Following the success of our seven previous IVI Congresses, we are pleased to invite you to the 8th IVIRMA International Congress that will be held in Palma de Mallorca, Spain, April 4th-6th, 2019.

This next edition is very special to us, since our merger with RMANJ allows us to join both companies’ forces and to combine strengths to share the latest research developments applied to the field of assisted reproduction.

Our aim is to continue providing top-level reproductive medicine congresses, addressing cutting-edge topics in this continuously evolving field of human reproduction and counting with the most reputable international speakers.

Palma de Mallorca is the capital city of the Balearic Islands, located in the Mediterranean sea. Palma de Mallorca will make you fall in love with its Mediterranean culture. The Balearics’ urban destination per excellence welcomes you with emblematic buildings such as the City Hall, the Cathedral, Bellver Castle, La Lonja, the Almudaina Palace and the Arab Baths, amongst others. Another way of experiencing the city is by visiting its churches. The Cathedral is the flagship, but there are many other parish churches that are worth visiting, such as San Jaime, Santa Eulàlia, San Miguel, San Nicolás and Santa Cruz.

The Mediterranean climate and food offer a wide variety of possibilities to enjoy your stay.

We hope you enjoy Palma, a bright and cheerful town, along with the hospitality of its people.

Prof. Antonio Pellicer
Prof. José Remohí
Prof. Richard Scott

Honorary Presidents
Committees

HONORARY PRESIDENTS

Prof. Antonio Pellicer
Prof. José Remohí
Prof. Richard Scott

CONGRESS PRESIDENT

Dr. Javier Marqueta

EXECUTIVE DIRECTOR

Mr. Miguel Tablado

SCIENTIFIC COMMITTEE

Chairman
Prof. Juan Antonio García-Velasco

Scientific Director
Prof. Emre Seli

Scientific Secretary
Mrs. María Delgado

Scientific Committee Members
Prof. José Bellver
Dr. César Díaz
Prof. Human Fatemi
Prof. Jason Franasiak
Dr. Nicolás Garrido
Dr. Jim Hotaling
Prof. Juan Antonio García-Velasco
Dr. Marcos Meseguer
Prof. Antonio Pellicer
Prof. José Remohí
Dr. Antonio Requena
Prof. Carlos Simón
Dr. Dagan Wells
**Pre-Congress Workshop. Program Overview**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:40</td>
<td>CONTROVERSIES IN MALE REPRODUCTIVE MEDICINE</td>
</tr>
<tr>
<td>10:40-11:10</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>11:10-13:10</td>
<td>CONTROVERSIES IN MALE REPRODUCTIVE MEDICINE</td>
</tr>
</tbody>
</table>

**Congress. Program Overview**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:40</td>
<td>CONTROVERSIES IN MALE REPRODUCTIVE MEDICINE</td>
</tr>
<tr>
<td>10:40-11:10</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>11:10-13:10</td>
<td>CONTROVERSIES IN MALE REPRODUCTIVE MEDICINE</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-10:00</td>
<td>SESSION IIIa: Implantation</td>
</tr>
<tr>
<td>08:00-10:30</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>10:30-12:00</td>
<td>SESSION IVa: Surgery</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>CONTROVERSY: Deep endometriosis – surgery vs ART</td>
</tr>
<tr>
<td>13:00-13:30</td>
<td>INTERNATIONAL IVI FOUNDATION RESEARCH AWARDS PRESENTATION</td>
</tr>
<tr>
<td>13:30-14:30</td>
<td>LUNCH</td>
</tr>
<tr>
<td>14:30-16:30</td>
<td>SESSION V: Hot Topics I</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>17:00-18:30</td>
<td>SESSION VI: Hot Topics II</td>
</tr>
<tr>
<td>18:30-19:30</td>
<td>CONTROVERSY: Should we transfer mosaic embryos in 2019?</td>
</tr>
</tbody>
</table>

**Saturday April 6th, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td>SESSION VII: Male Factor</td>
</tr>
<tr>
<td>10:00-10:45</td>
<td>Industry Supported Symposia: Ferring</td>
</tr>
<tr>
<td>10:45-11:15</td>
<td>Ovarian stimulation: Treating the extremes</td>
</tr>
<tr>
<td>11:15-13:45</td>
<td>SESSION VIII: Future directions</td>
</tr>
</tbody>
</table>
Pre-Congress Workshop: Scientific Program

THURSDAY, APRIL 4TH 2019

Menorca Room

08:30-10:40 CONTROVERSIES IN MALE REPRODUCTIVE MEDICINE
Chairs: S. Luján, Spain / C. Niederberger, USA

08:30-08:40 Introduction
   C. Niederberger, USA
08:40-09:00 Evaluate the male: need or useless?
   J. Hotaling, USA
09:00-09:10 Questions and answers
09:10-09:30 Pre-TESE: natural or stimulated spermatogenesis?
   C. Niederberger, USA
09:30-09:40 Questions and answers
09:40-10:00 To choose and process sperm for ART (What to do and not do)
   M. Meseguer, Spain
10:00-10:10 Questions and answers
10:10-10:30 Reconstructive surgery of the male: when and how to cut
   S. Luján, Spain
10:30-10:40 Questions and answers

10:40-11:10 COFFEE BREAK

11:10-13:10 CONTROVERSIES IN MALE REPRODUCTIVE MEDICINE
Chairs: N. Garrido, Spain / M. Meseguer, Spain

11:10-11:30 Extraction of sperm: what is the best way?
   C. Niederberger, USA
11:30-11:40 Questions and answers
11:40-12:00 To evaluate sperm in the laboratory: what is real and what is science fiction?
   N. Garrido, Spain
12:00-12:10 Questions and answers
12:10-12:30 Functional sperm from stem cells
   J. Medrano, Spain
12:30-12:40 Questions and answers
12:40-13:00 The future: what can we imagine?
   J. Hotaling, USA
13:00-13:10 Questions and answers
Congress: Scientific Program

THURSDAY, APRIL 4TH 2019

Auditorium Illes Balears

13:45-14:00 OPENING CEREMONY

14:00-16:00 SESSION I: OVARIAN STIMULATION
Chairs: J.A. García Velasco, Spain / A. Ruiz, Spain

14:00-14:30 New concepts of ovarian stimulation: where are we today?
B. Fauser, Netherlands

14:30-15:00 Avoiding the LH surge: analogues vs progesterone
D. Kaser, USA

15:00-15:30 Duo Stim: a critical appraisal
F. Ubaldi, Italy

15:30-16:00 How intense should we stimulate the ovaries?
N. Polyzos, Spain

16:00-16:30 COFFEE BREAK

16:30-18:00 SESSION II: PREMATURE OVARIAN INSUFFICIENCY
Chairs: E. Labarta, Spain / G. Castillón, Spain

16:30-17:00 Genetics of premature ovarian insufficiency
A. Rajkovic, USA

17:00-17:30 Ovarian fragmentation for follicular activation (OFFA)
C. Díaz, Spain

17:30-18:00 Autologous stem cells for ovarian insufficiency
S. Herraiz, Spain

18:00-19:00 DEBATE I: CONTROVERSY: INDIVIDUALIZED OVARIAN STIMULATION: FEASIBLE OR NOT?
Chairs: F. Olivennes, France/ S. Soares, Portugal

Feasible position: E. Bosch, Spain vs. Not feasible position C. van Tilborg, Netherlands

19:00-19:45 INDUSTRY SUPPORTED SYMPOSIA: MERCK
CONTROLLING DETAILS IN ART: THE PATH TO OPTIMISE CLINICAL OUTCOMES

19:00-19:05 Introduction & closing
J. Serna, Spain

19:05-19:25 Optimising clinical and management efficiencies in ART
R. Aurell, Spain

19:25-19:45 Technological solutions to maximise compliance in the embryology lab
R. Holmes, USA

Exhibition Area

19:45-20:30 WELCOME RECEPTION
FRIDAY, APRIL 5TH 2019

**Auditorium Illes Balears**  
**Parallel Session**

**08:00-10:00**  
**SESSION IIIa: IMPLANTATION**  
**Chairs:** A. Salazar, Spain / B. Fauser, Netherlands

- **08:00-08:30**  
  Implantation failure: the embryo vs the endometrium  
  N. Macklon, UK

- **08:30-09:00**  
  Role of immune system in improving implantation  
  D. Alecsandru, Spain

- **09:00-09:30**  
  Microbiome and human reproduction: current status  
  C. Simón, Spain

- **09:30-10:00**  
  How parental weight excess affects reproduction  
  J. Bellver, Spain

**Auditorium Mallorca**  
**Parallel Session**

**08:00-10:00**  
**SESSION IIIb: EMBRIOLOGY**  
**Chairs:** F. Bronet, Spain / M. Florensa, Spain

- **08:00-08:30**  
  Embryo metabolism: past, present and future  
  D. Sakkas, USA

- **08:30-09:00**  
  Artificial intelligence to enhance time lapse  
  C. Hickman, UK

- **09:00-09:30**  
  Extracellular vesicles and their clinical application  
  R. Scott, USA

- **09:30-10:00**  
  Non invasive PGS: reality or dream?  
  E. Fragouli, UK

**10:00-10:30**  
**COFFEE BREAK**

**Auditorium Illes Balears**  
**Parallel Session**

**10:30-12:00**  
**SESSION IVa: SURGERY**  
**Chairs:** E. Bosch, Spain / K. Nouri, Austria

- **10:30-11:00**  
  Diagnosis of uterine malformations with an impact on ART  
  S. Vannuccini, Italy

- **11:00-11:30**  
  New approaches to thin endometrium  
  M. Ferrando, Spain

- **11:30-12:00**  
  Routine hysteroscopy before IVF: does it help?  
  Y. Khalaf, UK

**12:00-13:00**  
**DEBATE II: CONTROVERSY: DEEP ENDOMETRIOSIS – SURGERY VS ART**  
**Chairs:** D. de Ziegler, France / M. Fernández, Spain

**Surgery position:** H. Roman, France  
**vs ART position:** J. Serna, Spain
**Scientific Program**

**Auditorium Mallorca**

**Parallel Session**

**10:30-12:00** **SESSION IVb: EPIGENETICS AND AGING**

**Chairs:** N. Garrido, *Spain* / M. Torres, *Spain*

**10:30-11:00** Epigenetics - parental impact on the embryo  
S. Laurentino, *Germany*

**11:00-11:30** Impact of telomeres damage in ovarian aging  
E. Varela, *Spain*

**11:30-12:00** Epigenetics, telomeres and other genetic factors impacting assisted reproduction  
D. Wells, *UK*

**Auditorium Illes Balears**

**Parallel Session**

**13:00-13:30** **INTERNATIONAL IVI FOUNDATION RESEARCH AWARDS PRESENTATION**

**13:30-14:30** **LUNCH**

**14:30-16:30** **HOT TOPICS I**

**Chairs:** J. Krüssel, *Germany* / A. Requena, *Spain*

**14:30-15:00** Is freeze-all really better?  
A. Pinborg, *Denmark*

**15:00-15:30** Prepubertal fertility preservation: state of the ART  
R. Anderson, *UK*

**15:30-16:00** Should we freeze ovarian tissue or oocytes for fertility preservation?  
A. Pellicer, *Spain*

**16:00-16:30** Optimal cycle regimen for frozen embryo replacement  
H. Fatemi, *UAE*

**Session sponsored by**

**16:30-17:00** **COFFEE BREAK**

**17:00-18:30** **HOT TOPICS II**

**Chairs:** C. Colomé, *Spain* / H. Fatemi, *UAE*

**17:00-17:30** Pragmatic approach to the infertile PCO patient  
N. Macklon, *UK*

**17:30-18:00** Mitochondrial DNA quantity as a biomarker  
E. Fragouli, *UK*

**18:00-18:30** Nuclear transfer: new data and new indications  
G. Calderón, *Spain*

**18:30-19:30** **DEBATE III: CONTROVERSY: SHOULD WE TRANSFER MOSAIC EMBRYOS IN 2019?**

**Chairs:** R. Fanchin, *France* / F. Bronet, *Spain*

**Yes position:** F. Fiorentino, *Italy*  
**No position:** R. Scott, *USA*
SUNDAY, APRIL 6TH 2019

Auditorium Illes Balears — Parallel Session

08:30-10:00 SESSION VII: MALE FACTOR

Chairs: C. González, Spain / A. Pacheco, Spain

08:30-09:00 What to test in the male beyond classical sperm analysis
S. Luján, Spain

09:00-09:30 Association of male factor infertility with somatic health
C. Niederberger, USA

09:30-10:00 Microfluidic sperm sorting
J. Hotaling, USA

10:00-10:45 INDUSTRY SUPPORTED SYMPOSIA: FERRING
OVARIAN STIMULATION: TREATING THE EXTREMES

10:00–10:02 Welcome and introduction
S. Lavery, UK

10:02–10:22 Improving outcomes in poor responders: Quality vs quantity
N. Polyzos, Spain

10:22–10:42 Balancing safety with efficacy: A measured approach to ovarian stimulation in high responders
F. Cruz, Spain

10:42–10:45 Closing remarks
S. Lavery, UK

10:45-11:15 COFFEE BREAK

11:15-13:45 SESSION VIII: FUTURE DIRECTIONS

Chairs: C. Niederberger, USA / A. Pellicer, Spain

11:15-11:45 Gene editing using CRISPR/Cas
G. Marfany, Spain

11:45-12:15 Premise, pitfalls and regulation of human genome editing
K. Orwig, USA

12:15-12:45 Correction of disease causing mutations in preimplantation embryos
D. Wells, UK

12:45-13:15 Contribution of corpus luteum number to maternal vascular health and preeclampsia risk
F. von Versen-Höynck, Germany

13:15-13:45 Breakthrough lecture: Investigating cellular and molecular interactions at the maternal/fetal interface that mediate placentation
A. Moffett, UK
Comprometidos con la Reproducción Asistida
General Information

Venue

Palau De Congressos, Palma De Mallorca
Address: Carrer de Felicià Fuster, 2, 07006 Palma, Illes Balears
Tel: +34 971 62 69 00
https://www.melia.com/es/palau-de-congressos/home.html/

✈️ 0 floor Congress center

✈️ 1st floor Congress center

Scientific Program
Technical Secretariat

GRUPO PACIFICO
The power of meeting

Marià Cubí 4 – Pral
08006 - Barcelona (Spain)
Tel: 932.388.777 / Fax: 932.387.488
congress2019@ivirma.com

Registration & Hospitality Desk

The registration desk is located at the entrance of the venue (Hall Auditorium Mallorca, floor 0), and it will be open at the following times:

- Thursday, April 4th. From 12:30 to 19:45.
- Friday, April 5th. From 07:30 to 19:30.
- Saturday, April 6th. From 08:00 to 13:45.

Badge

A name badge will be provided on-site with your registration documents at the Technical Secretariat. Name badges must be visible and used at all times anywhere within the meeting venue, access may be denied to those not wearing the badge.

Certificates

- A certificate of attendance will be sent by email on Monday 8th April.
- Certificates of poster presentations can be downloaded individually from Wednesday, April 10th on the congress website. Only posters that have been presented at the congress will be available for the certificate.

EACCME Accreditation

The 8th International IVIRMA Congress, Palma de Mallorca, Spain, 04/04/2019-06/04/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 19 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
EACCME® credits
Please find below the breakdown of ECMEC®s per day:

- 04.04.2019 - 8.00
- 05.04.2019 - 8.00
- 06.04.2019 - 3.00

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day.

Exhibition Area

- A commercial exhibition will be open during Congress hours.
- Due to local regulations, access to this area is only granted to delegates who have the legal right to prescribe medicines.

Food & Beverage

Coffees will be served at the exhibition area according to the schedule published on the program.

- Thursday, April 4th. From 16:00 to 16:30.
- Friday, April 5th. From 10:00 to 10:30 and from 16:30 to 17:00.
- Saturday, April 6th. From 10:45 to 11:15.

Lunch will be served at the exhibition area on Friday, April 5th from 13:30 to 14:30.

On Thursday, April 4th at 19:45, once the sessions have been finished, the Welcome Reception will take place. A cocktail will be offered to all participants and exhibitors at the exhibition area.

Language & Simultaneous Translation

- English is the official language for the 8th International IVIRMA Congress.
- Simultaneous translation will not be available.

Liability

Upon registration, participants agree that neither the Organizing Committee nor the Technical Secretariat assume any liability. Participants should, therefore, arrange their own health and travel insurance.

Mobile Phones

Delegates are kindly requested to keep their mobile phones in flight mode in the rooms where scientific and educational sessions are being held.

Posters Abstracts Display

- Posters will be displayed on digital screens in the Exhibition Hall 2, together with the Internet Corner.
- Presenters must be registered in order to be allowed to display their posters.
- Certificates of poster presentations can be downloaded individually from Wednesday April, 10th, on the congress website. Only posters that have been presented at the congress will be available for the certificate.
Safety & Security

Please do not leave any bags or other personal belongings unattended at any time, whether inside or outside the session halls and exhibition area.

Sanitary Interest

The meeting has been declared of Sanitary Interest by the Ministry of Health, Social Services & Equality.

Smoking Policy

The congress is a non-smoking event. Participants are kindly requested not to smoke in the meeting venue, including the exhibition & posters area.

Speaker’s Room

- Speakers and chairpersons will have free access to a speakers room located in the Floor 3 (Formentera Room). This room will be fully equipped with computers in case you need to check or make any change in your presentation.
- Presentations should be brought in a CD or USB memory to be handed out to the technician. Please deliver your presentation at least 3 hours before the session, or in case of early morning sessions, the day before.
- Presentations including any video must be accompanied with the software needed to visualize it. Please check with the technician that the presentation is working properly in the congress computer system.

WiFi

WIFI internet connection will be available in the congress area free of charge.
- SSID: IVIRMA Congress
- Password: GEDEONBFL19
Comprometidos con la Reproducción Asistida
SUSTAINABILITY PLAN 8th INTERNATIONAL IVIRMA CONGRESS

In the last editions of the International IVI Congress, the content of the conference has been carefully chosen to promote the initiatives and projects developed by the IVI Foundation, through actions linked to sustainability and CSR.

To enhance such commitment, we have developed a Sustainability Plan as part of the organisation of the 8th International IVIRMA Congress, with the overall objective of fostering a culture committed and focused on sustainability, which will, little by little, spread beyond every process and action within the company.

In developing the sustainability strategy for the 8th International IVIRMA Congress, where the Sustainability Plan is one of its key pillars, we have considered feedback from the Special Interest Groups formed by: healthcare professionals and members of companies and other entities participating, members of the scientific community and speakers, product and service providers, IVIRMA Staff, NGOs and other groups beneficiaries of the actions within the IVI CSR, as well as public administrations and other entities involved with the conference event.

The sustainability of the IVIRMA Congress is based on four fundamental pillars:

- Circular economy: This primarily concerns reducing waste, encouraging recycling and investing in products manufactured under sustainability criteria.
- Climate change: The objective is to reduce greenhouse gas emissions through the efficient use of energy and renewable resources at the location and during the convention’s activities, as well as the promotion of non-motorized mobility, and the involvement of participants in actions that offset emissions.
- Natural Resources and local production: Here, we seek to promote the proper management of water resources and the prevention of food waste, in addition to encouraging the consumption of local foods.
- People: The Congress is planned on the basis of social and sustainability criteria, and the positive impact is increased by including suppliers in this Sustainability Plan, and promoting their fulfilment of the obligations contained therein.

This plan was designed around the Sustainable Development Goals (SDG), a global initiative launched by the UN, whose aim is to eradicate poverty, protect the planet and guarantee that everyone can enjoy peace and prosperity. Each action in the Plan is connected with one of these SDG.

Thousands of organizations and companies have joined this global call and the IVIRMA Congress also wants to contribute to its achievement.

The success of the IVIRMA Congress goes beyond its scientific legacy and includes the creation of a social and environmental legacy. At IVIRMA Global we want to make a positive impact on the planet and society.

Further information on the Sustainability Action Plan of the 8th International IVIRMA is available at the congress website www.ivirmacongress2019.com
List of Posters
List of Posters

P-01
ALTERED EXPRESSION OF THE KISSPEPTIN/KISS1R AND NEUROKININ B/NK3R SYSTEMS IN MURAL GRANULOSA AND CUMULUS CELLS OF PATIENTS WITH POLYCYSTIC OVARY SYNDROME
V. Blasco Rodríguez1, F. Pinto Pérez2, N. Prados Dodd1, L. Candenás De Luján2, M. Fernández Sánchez1.
1IVIRMA Sevilla, Sevilla, Spain; 2Instituto de Investigaciones Químicas, CSIC, Sevilla, Spain.

P-02
KIR-HLA-C MISMATCH AND NOT “IMMUNE REJECTION” EXPLAINS EMBRYO PLACENTATION FAILURE IN OOCYTE DONATION ART
D. Alecsandru1, A. Pacheco1, N. Garrido2, A. Barrio1, A. Fabris1, P. Aparicio1, A. Pellicer1, J.A. Garcia-Velasco1.
1IVIRMA, Madrid, Spain; 2IVI Foundation, Valencia, Spain; 3IVIRMA, Rome, Italy.

P-03
PERCENTAGES OF ANEUPLOIDIES BY AGE GROUPS ARE SIMILAR IN THE SUB-FERTILE POPULATION AND IN SPONTANEOUS PREGNANCIES THAT ENDS INTO ABORTION
Y. Cabello1, A. Villa2, E. Carrillo2, D. Ordonez1.
1Hospital Ruber Juan Bravo Quironsalud, Madrid, Spain; 2Hospital Ruber, Madrid, Spain.

P-04
PARENTAL HLA-C ALLOTYPES ARE PREDICTIVE OF PREGNANCY LOSS AFTER SINGLE EUPLOID EMBRYO TRANSFERS IN PATIENTS WITH INHIBITORY KIR GENOTYPES
D. Marin1, X. Tao2, L. Sun2, M. Yang2, Y. Zhan2, R. Scott1.
1IVIRMA New Jersey, Basking Ridge, United States; 2Foundation for Embryonic Competence, Basking Ridge, United States.

P-05
A HIGH RESOLUTION X CHROMOSOME COPY NUMBER VARIATION MAP IN FERTILE FEMALES AND WOMEN WITH PRIMARY OVARIAN INSUFFICIENCY
S. Yatsenko1, M. Wood-Trageser2, T. Chu1, H. Jiang1, A. Rajkovic3.
1Magee Womens Research Institute, University of Pittsburgh, United States; 2University of Pittsburgh, Pittsburgh, United States; 3University of California San Francisco, San Francisco, United States.

P-06
ASSOCIATION BETWEEN TRANSCRIPTIONAL STUDY OF RECEPTIVITY AND IMMUNOLOGICAL FUNCTIONALITY OF ENDOMETRIUM
G. Gutierrez1, D. Cotan2, A. Martinez Lara2, L. Barreiro2, E. Incera1, S. Mayol1, A. Pasqualini4, J. Horcajadas3.
1Inmunogenesis-Conicet, Buenos Aires, Argentina; 2Pronacera Therapeutics, Sevilla, Spain; 3SINAE, Sevilla, Spain; 4Halitus, Buenos Aires, Argentina.

P-07
MAPPING OF SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) ALONG A HETEROZYGOSITY PLOT CORRELATES WITH DNA COPY NUMBER IN COMPREHENSIVE CHROMOSOME SCREENING (CCS)
J. Kim1, C. Jalas2, B. Hanson1, A. Tiesg1, E. Osman1, S. Neal1, R. Scott, Jr1.
1IVIRMA of NJ, Basking Ridge, United States; 2FEC, Basking Ridge, United States.

P-08
A CASE REPORT OF FETOPLACENTAL MOSAICISM DETECTED AFTER CONFIRMATION ANALYSIS OF A POSITIVE NON-INVASIVE PRENATAL TESTING (NIPT) RESULT
N. Galindo1, M. Munoz1, L. Rodrigo2, M. Milan2, V. Legidos1, M. Martinez-Beltran1, I. Perez-Cano1, C. Rubio2.
1IVI, Alicante, Spain; 2IGENOMIX, Valencia, Spain.
P-09
IS PARENTAL CONSANGUINITY ASSOCIATED WITH LOW OVARIAN RESERVE AND HIGHER RATE OF ANEUPLOIDIES?
L. Melado1, A. Arnanz1, N. De Munck1, I. Elkhattib2, G. Mollá2, B. Lawrenz1, H. Mousavi Fatemi1.
1IVI Middle East, Abu Dhabi, United Arab Emirates; 2UAGI IVI Foundation, Valencia, Spain.

P-10
THE ROLE OF GNRH ANTAGONISTS IN INTRAUTERINE INSEMINATION: A 3-YEAR RETROSPECTIVE STUDY
A. Lera Ramírez1, L. Gil Guilién1, K.M. Pavón Sáenz1, D.C. Méndez Guevara1, A. Solé Mayoral1, A.M. Muñoz Ledesma1, P. Merino García1, J.M. Viter Estévez1, A.C. Acha Salazar1, M. García Yuste1, A.B. Rodríguez Bújez1, E. Mancha Heredero1, Y. Pascual Arévalo1, C.F. Montoya García2, M.C. Redondo Lorente1.
1Hospital Universitario Río Hortega, Valladolid, Spain; 2Hospital General Río Carrión, Palencia, Spain.

P-11
HOW DOES THE NATIONAL LEGAL FRAMEWORK SUPPORT SURROGACY AS AN OPTION OF CROSS BORDER REPRODUCTIVE CARE IN THE EU? OUR EXPERIENCE IN GREECE
Institute of Life IASO, Marousi, Athens, Greece.

P-12
ASSISTED REPRODUCTION TREATMENT IN A PATIENT WITH A HISTORY OF HYDATIDIFORM MOLE
L. Asensio Romero, M.J. García Rubio, M. Valiente Cortés, B. Martín Cabrejas, G. Serrano Olmedo, J.M. Moreno Cebeira, C. Martín Caballero.
Hospital Universitario Fundación de Alcorcón, Alcorcón, Spain.

P-13
DELTA FOLLITROPIN IN IVF CYCLE STIMULATION: A SERIES OF 59 CASES
Hospital 12 Octubre, Madrid, Spain.

P-14
EVALUATION OF THE EFFICIENCY OF CONTROLLED OVARIAN STIMULATION BY FORT IN PATIENTS CLASSIFIED ACCORDING TO POSEIDON GROUP CRITERIA WITH LOW RESERVE
S. Vazquez Rodriguez1, R. Garrido Casserras1, J. Escrig Estrems1, N. Pellicer De Castellví1, M. Duarte Perez1, J.M. Soler Torró2, R. Taroncher Dasi1, N. Blasco Ramos1, J.M. Rubio Rubio1.
1Human Reproduction Unit, Hospital La Fe Valencia, Spain; 2Health Direction Department, La Ribera Valencia, Spain.

P-15
RETROSPECTIVE ANALYSIS AND OUTCOMES OF 891 INTRAUTERINE INSEMINATIONS CYCLES PERFORMED BETWEEN 2013 AND 2018 IN URUGUAY
C. Virginia1, M. Jose2, O. Rosina3.
1Hospital de Clinicas. Clínica Ginecologica B. Facultad de Medicina. UdelaR. COSEM, Montevideo, Uruguay; 2Hospital Pereira Rossell, Montevideo, Uruguay; 3Fertilab. COSEM, Montevideo, Uruguay.

P-16
GROWTH HORMONE CO-TREATMENT EVALUATION IN IN VITRO FERTILIZATION IN POOR RESPONDING PATIENTS USING GNRH ANTAGONIST SHORT PROTOCOL
1Reproferty, São José dos Campos, Brazil; 2Fundação Universitária Vida Cristã, Pindamonhangaba, Brazil.
P-17
► ASSESSMENT OF DHEA SUPPLEMENTATION REGARDING THE OVARIAN RESPONSE OF POOR RESPONDING PATIENTS SUBMITTED TO THE OVARIAN HYPERESTIMULATION PROTOCOL
J.F.D. Macedo¹, M.R. Oliveira¹, L.M.O. Gomes¹, G.C.D. Macedo¹, G.C.D. Macedo¹, D.O. Gomes¹, C.D.D.S. Francisquini¹, B.O. Ambrogi¹, L.A. Quirino¹, S.I.S. Santos².
¹Reproferty, São José dos Campos, Brazil; ²Fundação Vida Cristã, Pindamonhangaba, Brazil.

P-18
► PHYSICAL ACTIVITY OF INFERTILE WOMEN BEFORE, DURING AND AFTER IN VITRO FERTILIZATION TREATMENT AND ITS EFFECT ON PREGNANCY OUTCOME
D. Sõritsa¹, A. Salumets², F.B. Ortega³, S. Altmæe⁴.
¹Elite Clinic, Tartu, Estonia; ²Competence Centre on Health Technologies, Tartu, Estonia; ³Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Granada, Spain; ⁴Department of Biochemistry and Molecular Biology, Faculty of Sciences, University of Granada, Granada, Spain.

P-19
► POOR OVARIAN RESPONSE IN POLYCYSTIC OVARY SYNDROME (PCOS) WITH LOW LEVEL OF ANTI MULLERIAN HORMONE (AMH) IN UNIVERSITY KEBANGSAAN MALAYSIA MEDICAL CENTRE
UKM Medical Center, Kuala Lumpur, Malaysia.

P-20
► THE URINE LH TEST DURING FINAL OOCYTE MATURATION IN EGG DONATION PROGRAMME
R. Streda, N. Mardesticova, L. Jelinkova, T. Mardesic.
Sanatorium Pranatol, Praque, Czech Republic.

P-21
► VITAMIN D DEFICIENCY IN OOCYTE DONORS AND ICSI TREATMENT OUTCOME IN OOCYTE DONOR RECIPIENTS
Embryolab Fertility Centre, Thessaloniki, Greece.

P-23
► AN INITIAL EVALUATION OF THE EFFICACY AND SAFETY OF RECOMBINANT FOLLICLE STIMULATION HORMONE DELTA IN A UK FERTILITY CLINIC
Hewitt Fertility Centre, Liverpool Women’s NHS Foundation Trust, Liverpool, United Kingdom.

P-24
► WHEN IN VITRO FERTILIZATION FAILS: IS INTRAUTERINE INSEMINATION A REASONABLE TREATMENT STRATEGY?
S. Neal, A. Tiegts, E. Osman, J. Kim, B. Hanson, M. Werner, R. Scott.
IVI/RMA New Jersey, Basking Ridge, NJ, United States.

P-25
► THE EFFECT OF OVARIAN RESPONSE ON CLINICAL PREGNANCY AND DELIVERY RATES IN AN OOCYTE DONOR POPULATION
B. Hanson, J. Kim, A. Tiegts, E. Osman, S. Neal, M. Werner, R. Scott.
RMA New Jersey, Basking Ridge, NJ, United States.
P-26
▶ INFLUENCE OF THE NUMBER OF DONATIONS ON THE SUCCESS OF THE EGG DONATION PROGRAM
IVI Zaragoza, Zaragoza, Spain.

P-27
▶ SPONTANEOUS OVULATION VERSUS HCG TRIGGERING FOR INTRAUTERINE INSEMINATION: A RETROSPECTIVE ANALYSIS
Università degli Studi di Padova, Padova, Italy.

P-28
▶ EFFECTS OF TESTOSTERONE ADMINISTRATION IN POOR RESPONDER PATIENTS UNDERGOING IVF
S. Mosele1, A. Vitagliano1, F. Esposito1, E. Riviello1, B. Bellamio1, A. Politi2, S. Borgato2, L. Marin2, G. Ambrosini2, A. Andrisani1.
1University of Padua, Padova, Clinica Ginecologica ed Ostetrica, PMA, Italy; 2University of Padua, Clinica Ginecologica di Padova, PMA, Italy.

P-29
▶ HIGHLY PURIFIED HUMAN MENOPAUSAL GONADOTROPIN (HPHMG) BEFORE DAY SEVEN IN A CORIFOLLITROPIN ALFA (CFA) STIMULATION PROTOCOL DOES NOT INCREASE THE NUMBER OF OOCYTES RETRIEVED
A. Salazar-Vera1, N. Garrido2, J.M. Vilar-Sánchez1, R. Quiroga-Gil1, A. Cejudo-Román1.
1IVIRMA Málaga, Málaga, Spain; 2IVIRMA Foundation, Valencia, Spain.

P-30
▶ IS THE PREGNANCY RATE BETTER WITH SOME GONADOTROPIN IN LOW RESPONDERS REGARDLESS OF THE WOMAN’S AGE?
K.M. Pavón Sáenz1, A. Lera Ramírez1, L. Gil Guillin1, A. Solè Mayoral1, D.C. Méndez Guevara1, A.M. Muñoz Ledesma1, M. García Yuste1, A.B. Rodríguez Bújez1, Y. Pascual Arévalo1, E. Mancha Heredero1, P.A. Merino García1, M. Santana Macías2, A. Álvarez González2, A.C. Acha Salazar1, J.M. Viteri Estévez1.
1Hospital Universitario Río Hortega, Valladolid, Spain; 2Hospital Universitario de Guadalajara, Guadalajara, Spain; 3Hospital Rio Carrión, Palencia, Spain.

P-31
▶ THE EFFICACY OF LONG-ACTING HUMAN GROWTH HORMONE IN POOR RESPONDERS
J.S. Mun1, K.Y. Moon2.
1Gaya Womens Clinic, Jinju, Republic of South Korea; 2Maria Feritility Hospital, Pusan, Republic of South Korea.

P-32
▶ OVARIAN RESPONSE IN PATIENTS WITH BREAST CANCER AFTER CONTROLLED STIMULATION
Hospital 12 de Octubre, Madrid, Spain.

P-33
▶ DUAL TRIGGER, AN EFFECTIVE SECOND LINE STRATEGY
Hospital 12 Octubre, Madrid, Spain.
P-34
► EVALUATION OF THE EFFICIENCY OF CONTROLLED OVARIAN STIMULATION BY FORT IN PATIENTS CLASSIFIED ACCORDING TO POSEIDON GROUP CRITERIA
R. Garrido Casserres1, S. Vazquez Rodriguez1, J. Escrig Estrems1, N. Pellicer De Castellvi1, M. Duarte Pérez1, J.M. Soler Torró2, R. Taroncher Dasí1, N. Blasco Ramos1, J.M. Rubio Rubio1.
1Human Reproduction Unit, Hospital La Fe Valencia, Spain; 2Health Department Direction, La Ribera, Valencia, Spain.

P-35
► LIVE BIRTH RATES AFTER IMMEDIATE AND DELAYED ELECTIVE FROZEN EMBRYO TRANSFER: A SYSTEMATIC REVIEW AND META-ANALYSIS
C. Marques, S. Reis Soares, S. Santos-Ribeiro.
IVIRMA, Lisboa, Portugal.

P-36
► THE IMPACT OF THE ECONOMIC RECESSION IN GREECE ON ASSISTED REPRODUCTION DEMAND
1Centre for Human Reproduction, Genesis Athens Clinic, Athens, Greece; 2Department of Physiology - Department of Obstetrics and Gynaecology, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 3Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 4Assisted Conception Unit, 2nd Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

P-37
► MAMMALIAN DEVELOPMENTAL PLASTICITY AFTER EMBRYO VITRIFICATION-TRANSFER PROCEDURE IS PATENT AT ADULTHOOD
Universitat Politècnica de València, Valencia, Spain.

P-38
► KIDSCORE™ D5 ALGORITHM AS AN ADDITIONAL TOOL TO MORPHOLOGIC ASSESSMENT AND PGT-A FOR EMBRYO SELECTION: A TIME-LAPSE STUDY
E. Gazzo1, F. Peña2, F. Valdez2, S. Sessarego2, A. Chung1, C. Bonomini1, M. Ascenzo1, M. Velit1, E. Escudero1.
1Inmater Clínica de Fertilidad, Lima, Peru; 2Genomics Perú, Lima, Peru; 3Inmater Clínica de Fertilidad, Lima, Ecuador.

P-39
► BLASTOCYST CONTRACTIONS ARE STRONGLY RELATED WITH ANEUPLOIDY, LOWER IMPLANTATION RATES AND SLOWER EMBRYO CLEAVAGE TIMING: TIME LAPSE STUDY
E. Gazzo1, F. Peña2, F. Valdez2, A. Chung1, M. Velit1, M. Ascenzo1, E. Escudero1.
1Inmater Clínica de Fertilidad, Lima, Peru; 2Genomics Perú, Lima, Peru.

P-41
► USE OF OOCYTE MATURATION IN VITRO (IVM) FOR A NARROW GROUP OF PATIENTS
NGC, Saint-Petersburg, Russian Federation.

P-42
► CURRENT CRITERIA FOR OPTIMIZING INCUBATOR PARAMETERS
M. Ortega-Llarena1, K.B. Ng2, N. Macklon3, Y. Cheong3.
1VivoPlex Medical, Southampton, United Kingdom; 2University of Southampton Hospital, Princess Anne Hospital, Southampton, United Kingdom; 3London Women’s Clinic, London, United Kingdom.
P-43
► DAY 7 EUPLOID BLASTOCYSTS HAVE REDUCED MORPHOLOGIC GRADES AS COMPARED WITH DAY 5 AND 6 BLASTOCYSTS BUT SATISFACTORY SUSTAINED IMPLANTATION
A. Tiegs¹, L. Sun², S. Neal¹, E. Osman¹, J. Kim¹, B. Hanson¹, R. Scott¹.
¹IVI-RMA, Basking Ridge, United States; ²Foundation for Embryonic Competence, Basking Ridge, United States.

P-44
► DO VARIATIONS EXIST IN FERTILIZATION, BLASTULATION, AND SUSTAINED IMPLANTATION RATES BY INTRACYTOPLASMIC SPERM INJECTION (ICSI) OPERATOR?
A. Tiegs, B. Bauman, S. Neal, E. Osman, J. Kim, B. Hanson, R. Scott.
IVI-RMA, Basking Ridge, United States.

P-45
► EXTRACELLULAR VESICLES CAN BE ISOLATED FROM CULTURE MEDIA WITH AND WITHOUT EXPOSURE TO HUMAN PREIMPLANTATION EMBRYOS
D. Marin, E. Seli, R. Scott.
IVIRMA New Jersey, Basking Ridge, United States.

P-46
► RELATIONSHIP BETWEEN THE INNER CELL MASS (ICM) OF BLASTOCYST WITH SUCCESS OF THE SINGLE EMBRYO-TRANSFER
P. De Castro San Segundo, Y. Cabello, D. Ordoñez.
Hospital Ruber Juan Bravo Quironsalud, Madrid, Spain.

P-47
► ENDOMETRIAL SCRATCH INJURY FOR WOMEN WITH ONE OR MORE PREVIOUS FAILED EMBRYO TRANSFERS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Università Degli Studi di Padova, Padova, Italy.

P-48
► ULTRASOUND-GUIDED EMBRYO TRANSFER (ET): SUMMARY OF THE EVIDENCE AND NEW PERSPECTIVES. A SYSTEMATIC REVIEW AND META-ANALYSIS
University of Padua, SDB, Centro PMA, Padova, Italy.

P-49
► TRACTOCILE CAN IMPROVE PREGNANCY AND IMPLANTATION RATES IN FROZEN EMBRYO TRANSFERS OF PATIENTS WITH RECURRENT IMPLANTATION FAILURE AND HIGH NUMBER OF UTERINE CONTRACTIONS
IPGO, São Paulo, Brazil.

P-50
► RECEIPIENTS OF DONOR OOCYTES HAVE SIMILAR OUTCOMES USING FRESH OR VITRIFIED OOCYTES IN AN EGG DONATION PROGRAM
IPGO, São Paulo, Brazil.
P-51
TOTAL, MITOCHONDRIAL DNA (MTDNA) CONTENT DECREASES ALONG EMBRYO DEVELOPMENT, INSIGHTS OF MTDNA TURNOVER IN HUMAN PREIMPLANTATION DEVELOPMENT
M. Pérez-Sánchez1, M.F. Insúa1, A. Díez-Juan2, A. Mercader1, J. Bellver1, L. Escrich1, A. Pellicer1, M.J. De Los Santos1.
1IVIRMA Global, Valencia, Spain; 2GENOMIC, Valencia, Spain.

P-52
INCREASE OF BLASTOCYST RATE WHEN ENVIRONMENT CONDITIONS ARE IMPROVED DURING HANDLING OF OOCYTES AND PRE-EMBRYOS IN AN IVF TREATMENT
IVI RMA Seville, Seville, Spain.

P-53
REMOVAL OF ANTIBIOTICS ALLOWS VIABLE BACTERIA SURVIVAL IN CRYOPRESERVED EMBRYOS AFTER LONG-TERM STORAGE
X. García-Dominguez1, L. Montoro-Dasi2, J.S. Vicente1, C. Marín2, F. Marco-Jiménez1.
1Universitat Politècnica de València, Valencia, Spain; 2Universidad CEU-Cardenal Herrera, Alfara del Patriarca, Spain.

P-54
CLINICAL EXPERIENCE ON GV-RESCUE. PART I: LABORATORY AND CLINICAL OUTCOMES
A. Galán1, S. Pérez Albalá1, M.J. De Los Santos1, M.J. Escrivá1, A. Pellicer2, L. Escrich1.
1IVIRMA Valencia, Valencia, Spain; 2IVIRMA Roma, Roma, Italy.

P-55
CLINICAL EXPERIENCE ON GV-RESCUE. PART II: DEFINING BENEFITED PATIENT PROFILE
IVIRMA Valencia, Valencia, Spain.

P-56
MITOCHONDRIAL DNA CONTENT OF CLEAVAGE STAGE EMBRYOS AND THEIR RELATION TO PREIMPLANTATION DEVELOPMENT AND ANEUPLOIDY
A. Bayram1, N. Demunck1, I. Elkhatib1, A. Arnanz1, A. Linan2, B. Lawrenz1, H. Fatemi1.
1IVIRMA Middle East Fertility Clinic, Abu Dhabi, United Arab Emirates; 2IVIRMA Middle East Fertility Clinic, Muscat, Oman.

P-57
IMPROVEMENT OF ENDOMETRIAL RECEPTIVITY THROUGH THE USE OF AUTOLOGOUS PLATELET-DERIVED MICROPARTICLES
E. Garrijo Lopez, L. Garcia Bernardo, F. Galera Fernandez.
Instituto Madrileño de Fertilidad (IMF), Madrid, Spain.

P-58
IS THE PRESENCE OF A LYMPHOCITARY INFILTRATION IN THE SCRATCH INJURY BENEFICIAL IN THE RECURRENT IMPLANTATION FAILURE?
L. Barrero Real1, E. García García1, L. Pérez Gallego2, M.A. Angel Miñarro3, V. Pascual Escudero4, J.A. Gobernado Tejedor1, L. Rodríguez-Tabernero Martín1, A.B. Casas Marcos1, E.M. Bayón Alvarez1, J.M. Molina Villar1, R. Velázquez Barbado1.
1Hospital Clínico Universitario Valladolid, Unidad de Reproducción Humana Asistida Clínico Valladolid, Spain; 2Hospital Clínico Universitario Valladolid, Servicio de Anatomía Patológica, Spain; 3Facultad de Medicina, Facultad de Medicina, Spain; 4Hospital Clínico Universitario Valladolid, Servicio de Ginecología y Obstetricia, Spain.
P-59
► SPONTANEOUS PREGNANCY AFTER TREATMENT OF ASHERMAN SYNDROME
L. Asensio Romero, M.J. García Rubio, M. Valiente Cortés, B. Martín Cabrejas, G. Serrano Olmedo, J.M. Moreno Cebeira, C. Martín Caballero.
Hospital Universitario Fundación de Alcorcón, Alcorcón, Spain.

P-60
► IS CHRONIC ENDOMETRITIS A POSSIBLE ETIOLOGY OF THE REPEATED IMPLANTATION FAILURE?
E. García García1, L. Barrero Real1, L. Pérez Gallego1, M.A. Ángel Miñarro2, V. Pascual Escudero1, J. Gobernado Tejedor1, L. Rodríguez Taberner1, A.B. Casas Marcos1, E. Bayón Álvarez1, J.M. Fernández Gómez1, M.C. Del Pino Ortega1.
1Hospital Clínico Universitario de Valladolid, Valladolid, Spain; 2Facultad de Medicina de Valladolid, Valladolid, Spain.

P-61
► RECTAL AND VAGINAL PROGESTERONE HORMONAL REPLACEMENT THERAPY (HRT) FOR FROZEN EMBRYO TRANSFER – A PROSPECTIVE COHORT STUDY
B. Alsbjerg1, L. Thomsen2, H.O. Elbaek2, R. Laursen2, B.B. Povlsen2, T. Haahr2, P. Humaidan2.
1Fertility Clinic, Skive Regional Hospital, Roslev, Denmark; 2Fertility Clinic, Skive Regional Hospital, Skive, Denmark.

P-62
► OVARIAN STIMULATION IN PATIENT WITH PREMATURE OVARIAN INSUFFICIENCY
Hospital Universitario Virgen de las Nieves, Granada, Spain.

P-63
► INVESTIGATING THE PROGNOSTIC VALUE OF AGE 35 AS A CUT-OFF POINT REGARDING DECISION MAKING IN IN VITRO FERTILIZATION TREATMENT: A RETROSPECTIVE DATA ANALYSIS
1Department of Physiology - Department of Obstetrics and Gynaecology, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 2Centre for Human Reproduction, Genesis Athens Clinic, Athens, Greece; 3Unit of Endocrinology, Diabetes Mellitus and Metabolism, 2nd Department of Obstetrics and Gynecology, Aretaieion Hospital and Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 4Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 5Unit of Endocrinology, Diabetes Mellitus and Metabolism, 2nd Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

P-64
► GESTATION RATE IN WOMEN WITH LOW OVARIAN RESERVE AT PUBLIC HOSPITAL NOT RUNNING OOCYTE ACCUMULATION TECHNIQUES
Hospital Universitario Río Hortega, Valladolid, Spain.
P-65
► NEW INSIGHT INTO THE ROLE OF MILD THYROID ABNORMALITIES IN RECURRENT PREGNANCY LOSS
1Department Of Obstetrics and Gynaecology, Policlinico Casilino Hospital, Rome, Italy; 2Department of Biomedicine and Prevention Obstetrics and Gynecological Clinic, University of Rome “Tor Vergata” Italy, Rome, Italy; 3Department of Obstetrics and Gynaecology, Policlinico Casilino Hospital, University of Rome “Tor Vergata” Italy, Rome, Italy.

P-66
► IS INSULIN RESISTANCE A CONTRIBUTING FACTOR TO RPL?
E. Vaquero Martin1, N. Lazzarin2, B. Valentini3, H. Valensise3.
1Department of Biomedicine and Prevention Obstetrics and Gynecological Clinic, University of Rome “Tor Vergata” Italy, Rome, Italy; 2Department of Obstetrics and Gynaecology, Policlinico Casilino Hospital, University of Rome “Tor Vergata” Italy, Rome, Italy; 3Department of Obstetrics and Gynaecology, Policlinico Casilino Hospital, University of Rome “Tor Vergata” Italy, Rome, Italy.

P-68
► IMPACT OF THYROID AUTOANTIBODIES AND THYROID FUNCTION ON CLINICAL IVF OUTCOME
K.Y. Moon1, B.C. Jee2, S.H. Kim2.
1Maria Fertility Hospital, Pusan, Republic of South Korea; 2Seoul National University College of Medicine, Seoul, Republic of South Korea.

P-69
► PILOT STUDY INVESTIGATING BASAL SERUM PROGESTERONE AS PROGNOSTIC CRITERION OF FROZEN THAWED EMBRYO TRANSFER OUTCOME WITH PGT-A
D. Obidniak1, A. Gzgzyan2, A. Kalugina1, D. Niauri2.
1AVA Peter” Clinic, Saint-Petersburg, Russian Federation; 2Saint Petersburg State University, Medical Faculty, Saint-Petersburg, Russian Federation.

P-70
► CRYO-THAWED EMBRYO TRANSFER: ENDOMETRIUM PREPARATION AND FACTORS THAT INFLUENCE IN PREGNANCY RESULTS
Hospital Universitario Rio Hortega, Valladolid, Spain.

P-71
► GESTATION AFTER TREATMENT OF MALE HYPOGONADOTROPIC HYPOGONADISM
D. Sáez De La Mata, S. Sessa Mendez, A. Gaitero Martinez, M.V. Herranz Izquierdo, F.M. Ros Berruezo, J.M. Martínez De María.
Hospital Sanitas La Moraleja, Alcobendas, Madrid, Spain.

P-72
► PREDICTIVE VALUE OF SERUM PROGESTERONE LEVEL ON DAY 4, DAY 7 AND DAY 11 AFTER BLASTOCYST TRANSFER IN A HORMONAL REPLACEMENT THERAPY CYCLE
E. Labarta, G. Mariani, E. Bosch.
IVI RMA, Valencia, Spain.
P-73  
ASSOCIATIONS OF SEMEN QUALITY AND OXIDATION REDUCTION-POTENTIAL WITH CONCENTRATION OF CADMIUM, LEAD AND MERCURY IN SEMINAL PLASMA  
A. Wdowiak¹, A. Mroczkowski², S. Bakalczyk³.  
¹Medical University of Lublin, Lublin, Poland; ²Ovum Ria Lublin, Lublin, Poland.

P-74  
SPERM HEAD VACUOLE-LIKE STRUCTURES: IMPACT OF SEMEN MICROBIOME AND EXPOSURE TO ENVIRONMENTAL TOXICANTS  
O. Gaspard¹, C. Pirard², L. Dewalque³, V. Gridelet⁴, C. Jouan⁴, P. Gavage⁴, F. Thonon⁴, S. Ravet¹, F. Wenders¹, S. Labied⁴, L. Henry⁴, C. Charlier², S. Perrier D'hauterive⁴, M. Nisolle¹.  
¹Centre de Procréation Médicalement Assistée, CHU Liège, Belgium; ²Service de Toxicologie Clinique, CHU Liège, Belgium; ³Laboratoire de Biologie Clinique, CHR Liège, Belgium.

P-76  
OPTIMIZING THE PROTOCOL FOR VITRIFICATION OF INDIVIDUAL SPERMATOZOA BY ADJUSTING EQUILIBRATION TIME  
M. Belenky¹, D. Itzhakov¹, A. Berkovitz².  
¹MFC Male Fertility Center, Rishon LeZion, Israel; ²Assuta Medical Center, Rishon LeZion, Israel.

P-78  
IS THE TELOMERE PATHWAY IMPLICATED IN MALE FERTILITY? PRELIMINARY RESULTS  
C. Balmori¹, G. De Alba¹, I. Sánchez De La Puerta², A. Pacheco³, J.A. Garcia Velasco³, E. Varela².  
¹Rey Juan Carlos University, Madrid, Spain; ²IVIRMA, Madrid, Spain; ³Alfonso X El Sabio University, Madrid, Spain.

P-79  
MOLECULAR DIAGNOSIS OF RESISTANCE TO CRYOPRESERVATION IN SEMEN DONORS  
E. Sellés¹, P. Hernández-Vargas¹, N. Garrido², F. Vilella², I. Pérez², M. Muñoz¹.  
¹IVIRMA, Alicante, Spain; ²IVI Foundation, Valencia, Spain; ³IGENOMIX, Valencia, Spain.

P-80  
EMBRYONIC ANEUPLOIDY RATES IN PATIENTS UTILIZING SURGICAL SPERM ARE EQUIVALENT TO THOSE UTILIZING EJACULATED SPERM FOR IN VITRO FERTILIZATION (IVF) CYCLES  
E. Osman¹, S. Neal¹, A. Tieg³, J. Kim¹, B. Hanson¹, M. Werner¹, L. Sun², J. Franasík¹, R. Scott¹.  
¹IVI RMA, Basking Ridge, United States; ²Foundation for Embryonic Competence, Basking Ridge, United States.

P-81  
THE ‘REAL WORLD DATA’ ON USAGE OF FROZEN EGGS ON SOCIAL(ELECTIVE) PURPOSES IN KOREA: EXPERIENCE OF SINGLE PRIMARY CENTER  
C.W. Choo¹, J. Park², S.K. Kim³, W.D. Lee¹, J.H. Lim¹.  
¹Seoul Maria Hospital, Seoul, Republic of South Korea; ²Sarang I Infertility Clinic, Seoul, Republic of South Korea; ³Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of South Korea.

P-82  
PRESERVATION OF FERTILITY BREAST CANCER VS OTHER CAUSES  
Hospital Universitario Virgen de las Nieves, Granada, Spain.
P-83

LAPAROSCOPIC RADICAL TRACHELECTOMY FOR FERTILITY PRESERVATION IN CERVICAL CANCER
S. Dobbs, I. Harley, E. Craig, H. Nagar, M. Mccomiskey.

Belfast City Hospital, Belfast, United Kingdom.

P-84

FERTILITY PRESERVATION PROGRAM FOR ONCOLOGIC PATIENTS IN OUR UNIT: 2 YEARS OF EXPERIENCE

SACYL, Hospital Clínico Universitario de Valladolid, Spain.

P-85

MMP-9 LEVELS AND ENDOMETRIOSIS FERTILITY INDEX IN INFERTILE WOMEN WITH ENDOMETRIOSIS

1Ankara Dr. Sami Ulus Obstetrics and Gynecology and Pediatrics Hospital, Ankara Dr. Sami Ulus Obstetrics and Gynecology and Pediatrics Hospital, Ankara Dr. Sami Ulus Obstetrics and Gynecology and Pediatrics Hospital, Ankara, Turkey; 2Ufuk University Faculty of Medicine, Ankara, Turkey.

P-86

CASE REPORT: ETHANOL SCLEROTHERAPY FOR TREATING ENDOMETRIOMAS IN PATIENT WITH PRIMARY STERILITY

Hospital Universitario Virgen de las Nieves, Granada, Spain.

P-87

MULTIPLE PREGNANCY AFTER IN VITRO FERTILIZATION IN A PATIENT WITH OVARIAN POLYCYSTIC SYNDROME, OVARIAN AND DEEP ENDOMETRIOSIS, ADENOMYOSIS AND UTERINE MYOMATOSIS

Hospital La Paz, Madrid, Spain.

P-88

WOMEN WITH ENDOMETRIOSIS HAVE WORSE RESULTS IN IVF TECHNIQUES IN OUR CENTER?

Hospital Universitario Virgen de las Nieves, Granada, Spain.

P-89

ENDOMETRIOSIS: SURGERY OR EXPECTANT HANDLING BEFORE ARTIFICIAL INSEMINATION

Hospital Universitario Virgen de las Nieves, Granada, Spain.

P-90

ENDOMETRIOMAS IN INFERTILE WOMAN: IS ETHANOL SCLEROTHERAPY A GOOD OPTION FOR TREATMENT?

Virgen de las Nieves University Hospital, Granada, Spain.
Supporters and Exhibitors
Meet us on April 4 at 19:00h in our talk about “Controlling details in ART, the path to optimise clinical outcomes” with Ramón Aurell, Rebecca Holmes and José Serna as chairman.

Download the products data sheets here
Supporters

Presidential circle

FERRING

PRODUCTOS FARMACÉUTICOS

Gedeon Richter

Gold

Merck

Silver

Angelini

IBSA

Caring Innovation
From conception to birth...

A product portfolio that addresses the needs of the entire patient journey

Working to address unmet needs in reproductive health

Partners with leading international and local organisations to expand education and treatment access
Exhibitors

BioCare Europe

COOK MEDICAL

CooperSurgical
Fertility and Genomic Solutions

Igenomix

STORZ
KARL STORZ — ENDOSKOPE

KITAZATO | Dibimed

LogixX Pharma

OLYMPUS
Your Vision, Our Future

Theramex
For Women, For Health

Vitrolife
From conception to birth...

A product portfolio that addresses the needs of the entire patient journey

Working to address unmet needs in reproductive health

Partners with leading international and local organisations to expand education and treatment access
**Floorplan**

<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biocare</td>
<td>13</td>
</tr>
<tr>
<td>CookMedical</td>
<td>34</td>
</tr>
<tr>
<td>CooperSurgical</td>
<td>15+16</td>
</tr>
<tr>
<td>Ferring</td>
<td>25+26+27+28</td>
</tr>
<tr>
<td>Fundación Turismo Palma 365</td>
<td>17</td>
</tr>
<tr>
<td>Gedeon Richter</td>
<td>5+6+7+8</td>
</tr>
<tr>
<td>Ibsa</td>
<td>1+2+3+4</td>
</tr>
<tr>
<td>Igenomix</td>
<td>21+22</td>
</tr>
<tr>
<td>IVI Global Education</td>
<td>41</td>
</tr>
<tr>
<td>IVI International</td>
<td>42</td>
</tr>
<tr>
<td>Karl Storz</td>
<td>19</td>
</tr>
<tr>
<td>Kitazato - Dibimed</td>
<td>23+24</td>
</tr>
<tr>
<td>LogixX Pharma</td>
<td>36</td>
</tr>
<tr>
<td>Médicos sin fronteras</td>
<td>14</td>
</tr>
<tr>
<td>Merck</td>
<td>9+10+11+12</td>
</tr>
<tr>
<td>MSD</td>
<td>29+30+31+32</td>
</tr>
<tr>
<td>Olympus</td>
<td>33</td>
</tr>
<tr>
<td>Theramex</td>
<td>37+38+39+40</td>
</tr>
<tr>
<td>Vitrolife</td>
<td>35</td>
</tr>
</tbody>
</table>
Welcome to the future of fertility

The needs of fertility treatment are changing. Like you, we believe women should be offered solutions that adapt to these needs.

Bemfola (follitropin alfa) is an r-hFSH that delivers both quality and value in a patient-preferred pen.

Through our combined expertise, we provide the services that allow women to receive the treatment they deserve, today and tomorrow.

Together. Supporting patients on the journey ahead.

Click here for the full Summary of Product Characteristics
## Supported Symposia

### THURSDAY, APRIL 4TH 2019
**MERCK SPONSORED SYMPOSIUM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:00-19:45</td>
<td>CONTROLLING DETAILS IN ART: THE PATH TO OPTIMISE CLINICAL OUTCOMES</td>
</tr>
<tr>
<td>19:00-19:05</td>
<td>Introduction &amp; closing</td>
</tr>
<tr>
<td></td>
<td>J. Serna, Spain</td>
</tr>
<tr>
<td>19:05-19:25</td>
<td>Optimising clinical and management efficiencies in art</td>
</tr>
<tr>
<td></td>
<td>R. Aurell, Spain</td>
</tr>
<tr>
<td>19:25-19:45</td>
<td>Technological solutions to maximise compliance in the embryology lab</td>
</tr>
<tr>
<td></td>
<td>R. Holmes, USA</td>
</tr>
</tbody>
</table>

### SATURDAY, MAY 6TH 2019
**FERRING SPONSORED SYMPOSIUM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-10:45</td>
<td>OVARIAN STIMULATION: Treating the extremes</td>
</tr>
<tr>
<td>10:00-10:02</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td></td>
<td>S. Lavery, UK</td>
</tr>
<tr>
<td>10:02-10:22</td>
<td>Improving outcomes in poor responders: Quality vs quantity</td>
</tr>
<tr>
<td></td>
<td>N. Polyzos, Spain</td>
</tr>
<tr>
<td>10:22-10:42</td>
<td>Balancing safety with efficacy: A measured approach to ovarian stimulation in high responders</td>
</tr>
<tr>
<td></td>
<td>F. Cruz, Spain</td>
</tr>
<tr>
<td>10:42-10:45</td>
<td>Closing remarks</td>
</tr>
<tr>
<td></td>
<td>S. Lavery, UK</td>
</tr>
</tbody>
</table>
Supporters Corporate Information

Presidential circle

**FERRING PHARMACEUTICALS**
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives.
Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology.
Ferring has been developing treatments for mothers and babies for over 50 years.
Today, over one third of the company’s research and development investment goes towards finding innovative and personalized healthcare solutions to help mothers and babies, from conception to birth.

📍 Company address
Ferring International Center S.A.
Ch. de la Vergognausaz 50. 1162 Saint-Prex, Switzerland

📞 Company Phone Number
+41 58 301 00 00

fax
+41 58 301 03 71

🌐 www.ferring.com

**GEDEON RICHTER**
Gedeon Richter Plc, headquartered in Budapest, Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. The product portfolio of Richter covers many important therapeutic areas, including Women’s healthcare, central nervous system, and cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter’s original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women’s healthcare field worldwide. Richter is also active in biosimilar product development.

📍 Company address
Gedeon Richter / Preglem
Route de Frontenex 41A, 1207 Geneva, Switzerland

📞 Company Phone Number
(+41) 22 884 03 51

fax
(+41) 22 884 03 50

📧 E-mail
info@gdnr.ch

🌐 http://www.richter.hu
MERCK SHARP & DOHME DE ESPAÑA S.A
For 125 years, MSD has been a global healthcare leader working to help the world be well. MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through our prescription medicines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.

Company address
C/Josefa Valcárcel 38, 28027, Madrid, España

Company Phone Number +34 913 210 600
Company Fax Number +34 913 210 700
E-mail msd_info@merck.com, pilar.parente@merck.com

www.msd.es

MERCK, S.L.U.
Merck is a leading science and technology company, active in Healthcare, Life Science and Performance Materials. Around 52,000 employees work all around the world to develop solutions that improve people’s lives and contribute to a sustainable future, such as technologies for advanced genetic edition, innovative therapies for difficult to treat diseases and smart devices. Merck Spain has three manufacturing sites: biotechnological, pharmaceutical and chemical. The company is committed, together with other social and business agents, to respond to local economic and social challenges, as the development of female talent, the promotion of scientific excellence and the changes that technology and innovation introduce in our society.

Company address
María de Molina, 40 2a planta. 28006 Madrid, Spain

Company Phone Number +34 91 745 44 00
Company Fax Number +34 91 745 44 44
Company E-mail: comunicacion@merckgroup.com

www.merck.es

IBSA INSTITUT BIOCHIMIQUE SA
IBSA is an international pharmaceutical company based in Lugano, Switzerland. Besides a full range of highly-purified gonadotrophins, IBSA’s portfolio includes a novel ingenious system for subcutaneously delivering progesterone in an aqueous solution. IBSA is able to guarantee the highest quality of its products over the years thanks to its complete in-house manufacturing process and a global quality system.

Company address
Via del Piano, 29 – CH-6915 Pambio-Noranco (Switzerland)

Company Phone Number +41 58 3601000

www.ibsagroup.com
FORWARD
(Funding Opportunity for Research Work Advancement in Reproductive Development)
is a €1 million grant offered over a 5-year period for innovative research proposals in reproductive medicine.

The grant is open to applications from all reproductive research institutions and IVF centres to fund research programmes with the potential to drive the field forward.

APPLY FOR A FORWARD GRANT

Applications for the next round of FORWARD Grant Awards are now open. Please apply on www.forwardgrant.com

OUR COMMITMENT TO FERTILITY

The availability of FORWARD research grants demonstrates the continued commitment of the Gedeon Richter Group to advancing the fertility field, for the benefit of patients seeking to become parents.
Inspired by nature
Exhibitors Corporate Information

**BIOCARE EUROPE**
Biocare Europe Srl is an Irvine Scientific company that offers all kind of products and services to IVF clinics in Europe.

- **Company address**
  Via Emilio Motta, 10. 20144, Milan
- **Company Phone Number**
  900 99 39 36
- **Company Fax Number**
  0644240358
- **E-mail**
  info_fbci@fujifilm.com, Emanuele.bracciani@fujifilm.com
- **Website**
  www.biocareeurope.com

**COOK MEDICAL**
Cook Medical is a family-owned medical device company that works with physicians to develop devices that are less invasive for patients.

- **Company address**
  O’Halloran Road, National Technology Park, Limerick, Ireland
- **Company Phone Number**
  +34 606 617 143
- **E-mail**
  Enrique.sanchez@cookmedical.com
- **Website**
  www.cookmedical.com

**COOPERSURGICAL FERTILITY AND GENOMIC SOLUTIONS**
CooperSurgical Fertility and Genomic Solutions is the global leader in IVF and reproductive genetics, providing innovative products and services for every step in the ART journey.

Building on the high-quality reputation of our legacy companies ORIGIO, SAGE, Humagen, The Pipette Company (TPC), K-Systems, Research Instruments (RI), Wallace®, LifeGlobal® and CooperGenomicsSM, we provide a trusted system of consumables, equipment, technologies and genetic testing for the complete ART process.

- **Company address**
  World Trade Center. Moll de Barcelona s/nª. Edificio Nord, Pl. 4ª, módulos 414-415 | 08039 Barcelona, Spain
- **Company Phone Number**
  +34 93 199 81 18 / +34 93 199 81 19
- **Company E-mail**
  informacion@coopersurgical.com
- **Website**
  www.coopersurgical.com
IGENOMIX
IGENOMIX is a company with broad experience in genetic and molecular diagnosis and one of the world references in these techniques. IGENOMIX’s efforts in R&D enable the company to create and develop specific proprietary tools to support professionals in the reproductive medicine field.

Company address
Ronda Narciso Monturiol, 11 B
Parque Tecnológico Paterna, 46980 – Paterna – Valencia

Company Phone Number
+34 963905310

E-mail
info@igenomix.com

www.igenomix.com

KARL STORZ ENDOSCOPIA IBERICA S.A.
Since its beginnings in 1945, the KARL STORZ family company has grown into a global manufacturer and distributor of endoscopes, medical instruments, and devices. We are no giant on an international scale but a leader in the things that matter: creativity, flexibility, and expertise. Our range of endoscopic instruments for human medicine, veterinary medicine, and industrial endoscopy now includes more than 15,000 products. The most recent KARL STORZ developments are in digital documentation systems and comprehensive operating room concepts. As a system supplier, the company combines its expertise in endoscopy with software solutions to achieve integration in the operating room and to support clinical process and resource management.

Company address

Company Phone Number
+34916771051

Company E-mail:
info-es@karlstorz.com

www.karlstorz.com

IVI INTERNATIONAL
IVI is one of the European centres with the best pregnancy rates: 9 out of 10 couples who put their trust in us achieve their objective. From traditional treatments such as Artificial Insemination and In Vitro Fertilisation to more innovative techniques such as Sperm Microinjection and the Embryoscope®, which IVI participated actively in developing.

Company address
C/ Colón, 1 – 4º Planta, 460004 Valencia, Spain

Company Phone Number
+34 963 17 36 10

Company E-mail:
international@ivi.com

www.ivi-fertility.com
IVI GLOBAL EDUCATION

Our aim at IVI Global Education is to transfer knowledge and expertise in Human Reproduction in order to promote it among health professionals. We are committed to placing students at the center of our activity to offer them the best training and education in the field of assisted reproduction. They will be immersed in an environment marked by the excellence of our educational system, which is always up-to-date, innovative and based on cutting-edge technologies.

Company address
Edif. Biopolo. Hosp. Univ. La Fé
Fernando Abril Martorell, 107 Torre A 1º
46026 Valencia (Spain)

Company Phone Number
+34 963 385 703

E-mail
education.info@ivirma.com

https://iviglobaleducation.com

KITAZATO - DIBIMED

Kitazato is a Corporation founded in Japan in 1996, involved in the research, the development and the manufacturing of biotechnological medical devices for assisted reproduction. In the last two decades, we developed products like the Cryotop® Method, which changed forever the work in an IVF lab. Dibimed is our partner and distributor in Europe, Russia, Latin America and Africa.

Company address
C/Luis Buñuel 1, office 4

Company Phone Number
(+34) 963 056 395

Company Fax Number
(+34) 963 056 396

E-mail
info@dibimed.com

https://www.kitazato-dibimed.com/

LOGIXX PHARMA

LogixX Pharma partners with pioneering semen diagnostics and treatment companies to help couples identify and combat male fertility issues: See us at Booth 36 or demonstrations for Lenshooke, world’s smallest fully automated semen analyser, MiOXSYS for oxidative stress and DxNow semen sorting plates.

Company address
Abbey House, 1650 Arlington Business Park, Theale, Reading, Berkshire. RG7 4SA

E-mail
info@logixxpharma.com

www.logixxpharma.com
OLYMPUS IBERIA S.A.U
True to Life - Olympus for IVF
Olympus is one of the world’s leading manufacturers of professional opto-digital products. With expertise throughout Life science and research, Olympus provides microscopes and cameras for routine tasks and high-end solutions for all IVF applications.

* Company address
  Amsinckstrasse 63, 20097 Hamburg

* Phone Number
  +49 40 237730

* Fax Number
  +49 40 233765

* E-mail
  ScientificSolutions@olympus-europa.com

* Web

THERAMEX
Theramex is a global specialty pharmaceutical company solely committed to supporting the health needs of women. By working closely with our partners and healthcare professionals, we provide a diverse portfolio of treatments that help women through each of their life stages. Theramex brings new and innovative solutions for contraception, fertility, menopause and osteoporosis.

* Company address
  Calle Alfonso XII, 62, 2ª Planta, 28014 Madrid

* Phone Number
  +34 911987399

* E-mail
  atencionalcliente@theramex.com

* Web
  [http://theramex.com/](http://theramex.com/)

VITROLIFE SWEDEN AB
We provide what you need to secure improved results throughout the IVF journey. The key to success in IVF is care. Care in retrieval and handling of gametes and embryos, culture and evaluation, cryopreservation and transfer. Our unbroken chain of innovative high quality products ensure optimal care at every step throughout the IVF treatment.

* Company address
  Box 9080, 40092 Gothenburg, Sweden

* Phone Number
  +46 31 721 80 00

* Fax Number
  +46 31 721 80 90

* E-mail
  info@vitrolife.com

* Web
  [www.vitrolife.com](http://www.vitrolife.com)